Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZoetisXSWX:ZTS +2.39%63 EV-to-OCF is 14.36 as of Jul. 17, 2026, which is 62% below its 10-year median of 37.71. GuruFocus rates XSWX:ZTS with a GF Score™ of 63/100 and a GF Value™ of CHF156.38 (Significantly Undervalued). Among 1,008 Drug Manufacturers companies, Zoetis ranks worse than 58.13% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Zoetis's Enterprise Value is CHF31,998 Mil.
Zoetis's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was CHF2,228 Mil. Therefore, Zoetis's EV-to-OCF for today is 14.36.
The historical rank and industry rank for Zoetis's EV-to-OCF or its related term are showing as below:
XSWX:ZTS'
s EV-to-OCF Range Over the Past 10 Years
Min: 13.85 Med: 37.71 Max: 53.92
Current: 14.17
During the past 13 years, the highest EV-to-OCF of Zoetis was 53.92. The lowest was 13.85. And the median was 37.71.
XSWX:ZTS's EV-to-OCF is ranked worse than 58.13% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.425
vs XSWX:ZTS: 14.17
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-17), Zoetis's stock price is CHF61.79.
Zoetis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF4.817. Therefore, Zoetis's PE Ratio (TTM) for today is 12.83.
Zoetis (XSWX:ZTS) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zoetis's share price for today is CHF61.79.
Zoetis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF4.817.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zoetis EV-to-OCF Related Terms
Zoetis EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Zoetis's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZTS vs UTHR, VTRS, NBIX: EV-to-OCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Zoetis's EV-to-OCF falls into.
Zoetis's current Enterprise Value is CHF31,998 Mil.
Zoetis's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2,228 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis (XSWX:ZTS) has a EV-to-OCF of 14.36 as of Jul. 17, 2026. This is 62% below median its historical median of 37.71. Over the past decade, Zoetis' EV-to-OCF has ranged from 13.85 to 53.92. According to the industry distribution chart, Zoetis ranks #586 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 58.1%.
Is Zoetis' EV-to-OCF too high?
Zoetis' current EV-to-OCF of 14.36 is 62% below median its 10-year median of 37.71. Over the past 10 years, this metric has ranged from a low of 13.85 to a high of 53.92. The Drug Manufacturers industry median EV-to-OCF is 10.43. Zoetis' value of 14.36 is 37.7% above this industry median. Based on the distribution chart, Zoetis ranks #586 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zoetis has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' EV-to-OCF compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #586 out of 1008 companies for EV-to-OCF. This places Zoetis in the lower half of its industry. The industry median EV-to-OCF is 10.43. Zoetis' value of 14.36 is 37.7% above this benchmark. Historically, Zoetis' own EV-to-OCF has ranged from 13.85 to 53.92 over the past decade. While the company's 10-year median is 37.71 vs. the industry median of 10.43, Zoetis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.43, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zoetis's current EV-to-OCF of 14.36 is 37.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current EV-to-OCF is 14.36, which is 62% below median its own 10-year median of 37.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF156.38, compared to a current price of CHF61.79 — trading 60.5% below its estimated fair value. The current EV-to-OCF is 14.36, which is 62% below median its 10-year median of 37.71 and 37.7% above the Drug Manufacturers industry median of 10.43. Zoetis' overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current EV-to-OCF is 14.36 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (XSWX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of CHF61.79 is trading 60.5% below its estimated GF Value™ of CHF156.38.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for XSWX:ZTS:
EV-to-OCF: 14.36 (62% below median its 10-year median of 37.71)
GF Value™: CHF156.38 vs. price of CHF61.79 (60.5% below fair value)
Industry Position: 37.7% above the Drug Manufacturers median (#586 of 1008)
No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
63GF Score
Get the complete analysis for XSWX:ZTS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZTS has been successfully added to your 
